Bed Bath & Beyond, Inc.
BBBYBed Bath & Beyond, Inc.'s three tracks disagree. Price, valuation and the earnings engine each tell a different story — the next quarter or two settles it.
Biggest watch item: the price is not yet in a confirmed uptrend — timing risk, not thesis risk.
The price is between stages. Underneath, the last four quarters read improving. What settles it: the next one or two quarters of delivery.
Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.
Bed Bath & Beyond, Inc. trades at $5.3, between stages. That is −10.5% against its own 200-day average. It sits at 12% of a 52-week range of $4 to $12. On relative strength it is currently behind the S&P 500 on a trailing-13-week view (3 weeks and counting).
Today the stock is between stages. At $5.3 it trades −10.5% versus its 200-day average and sits at 12% of its 52-week range ($4–$12).
Against the market, two honest reads. Cumulative: over the last 1.0 years the stock moved −32% while the S&P 500 moved +19% — behind the index over the full window. Recent form: on a trailing-13-week view the stock is currently behind (3 weeks and counting; last ahead the week of 2026-07-10) — the ribbon below is that same metric, week by week.
What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.
→ The trend is one thing; the bill is another. Are you paying up for it? Next: how the P/E reads against its own history.
Valuation P/E is the price of $1 of annual profit: how many dollars the market pays for each dollar the company earns in a year.
P/E does not price Bed Bath & Beyond, Inc. — earnings are negative, so there is no multiple to rank against its own history. The revenue and margin lines below are where a turn, when it comes, would show first. A P/E returns here the first period the bottom line turns positive.
With earnings negative, P/E does not price — there is no multiple to rank against its own history. The revenue and margin lines below are where the turn, when it comes, will show first.
Put together: the multiple is unremarkable against its own past, so the story rests on the earnings line underneath it, not the multiple.
→ Cheap or dear rides on the earnings. Are they actually growing? Next: the fundamental stage — where the business sits in its arc, and how growth has compounded.
Stage: No read Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).
Bed Bath & Beyond, Inc. reads as no read on its fundamental arc. Under eight usable quarters on the growth trio — not enough history for an honest trajectory read. The read is built from 12 quarters across 2 curves, on partial evidence.
Why it matters: with too little history, an honest page says so instead of guessing a trajectory.
Fewer than eight usable quarters on the growth curves — this page will not guess a trajectory from a stub of history.
| 1yr | 3yr | 5yr | 10yr | |
|---|---|---|---|---|
| Revenue | −25.2% | −18.6% | — | — |
| Stock price | −47.7% | — | — | — |
→ The stage names the trajectory. Next: the revenue line that produces it, quarter by quarter.
4-Factor Sector Score
35.7/100 — rank 25 of 28 in Specialty Retail · 59% evidence confidence
Bed Bath & Beyond, Inc. scores 35.7 out of 100 against the 28 companies it is compared with in Specialty Retail, ranking 25. Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
The four contributions add to the total exactly: 14.2 + 8.5 + 8.9 + 4.1 = 35.7. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.
What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.
Revenue Revenue is the top line: everything the company billed its customers in the period.
Bed Bath & Beyond, Inc. reported $0.3 B of revenue in the Mar 26 quarter, +8.7% year on year. Over 4 years it has compounded at −21.7% a year. The last full year, FY25, came in at $1.0 B. The last four reported quarters add to $1.1 B.
Bed Bath & Beyond, Inc. reported $0.3 B of revenue in the Mar 26 quarter, +8.7% year on year. Over 4 years it has compounded at −21.7% a year. The last full year, FY25, came in at $1.0 B. The last four reported quarters add to $1.1 B.
FY25 revenue came in at $1.0 B (−25.2% on the year), capping 4 years at −21.7% compound. The latest quarter (Mar 26) printed $0.3 B, +8.7% year on year.
Pace check: the last four quarters averaged −11.9% growth against the decade's −21.7% — the current year is running faster than its own long-run rate.
Acceleration check: trailing-twelve-month revenue grew −14.5% over the last 4 quarters against −17.3%/yr over the last 8 — stabilising.
→ Revenue grew — did margins hold as it scaled? Next: −8.0% this quarter (+0.7 pp YoY).
Operating margin Operating margin is what is left of every $100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.
Bed Bath & Beyond, Inc.'s operating margin is −8.0% in the Mar 26 quarter, +0.7 percentage points against the same quarter a year ago. Across 5 fiscal years the operating margin has ranged −12.9% to 4.0%. The current quarter sits inside that band.
Bed Bath & Beyond, Inc.'s operating margin is −8.0% in the Mar 26 quarter, +0.7 percentage points against the same quarter a year ago. Across 5 fiscal years the operating margin has ranged −12.9% to 4.0%. The current quarter sits inside that band.
The latest quarter's operating margin is −8.0%, +0.7 pp against the same quarter a year ago. Across 5 fiscal years the operating margin has ranged −12.9%–4.0%.
Why the margin moved: operating margin went +0.7 pp year on year while gross margin went −2.1 pp — the gain came mostly from the gross line: input costs and pricing.
→ Margins held — did that reach the bottom line? Next: profit null in the latest quarter.
Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.
Bed Bath & Beyond, Inc. posted a net loss of $0.02 B in the Mar 26 quarter. The full FY25 year was a loss of $0.1 B. That loss is 8.0% of the quarter's revenue. The same quarter a year earlier lost $0.04 B. 11 of the last 12 reported quarters were loss-making.
Bed Bath & Beyond, Inc. posted a net loss of $0.02 B in the Mar 26 quarter. The full FY25 year was a loss of $0.1 B. That loss is 8.0% of the quarter's revenue. The same quarter a year earlier lost $0.04 B. 11 of the last 12 reported quarters were loss-making.
Mar 26 profit was $−0.0 B, null year on year. On the full year, FY25 printed $−0.1 B (null).
→ Profit rose — but did the cash follow?
Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.
Bed Bath & Beyond, Inc.'s cash-flow history is too thin to judge how much reported profit converts into cash. In FY25 that was $−0.1 B of operating cash against $−0.1 B of profit. After $0.0 B of capital spending, $−0.1 B was left as free cash. Cash resolution here is annual, because quarterly cash statements are not published.
FY25: operating cash of $−0.1 B against reported profit of $−0.1 B, leaving free cash of $−0.1 B after $0.0 B of capital spending.
Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.
Router verdict: the visible cash user is investment — the next section checks what the spending is buying.
→ So follow the cash to where it goes. Next: $0.0 B of building over 3 years.
Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).
Bed Bath & Beyond, Inc. does not report the debtor, inventory and payable day-counts a cash cycle is built from, so this section reads the investment side instead. Capital spending ran $0.0 B over the last 3 years. Averaged over those years that is 0.0% of FY25 revenue a year.
Working-capital day-counts are not in our numbers for this stock, so this section reads the investment side — where the cash is being put to work.
On the investment side: capital spending of $0.0 B over the last 3 fiscal years.
The synthesis: the cash is going into capacity, not disappearing into the cycle — the question becomes whether the new capacity earns.
→ Does all this activity actually earn its cost of capital? Next: ROE is −35% and the ROIC − WACC spread is −99.1 pp.
Return on equity Return on equity (ROE) is the profit the business earns on its shareholders’ money. With the full capital-employed split not in our numbers, ROE is the cleanest long ladder we can draw here.
Bed Bath & Beyond, Inc. earns a ROE of −36% in FY25. That is up from a trough of −163% in FY24. Return on invested capital clears the cost of that capital by −99.1 percentage points, so growth here is not yet paying for the capital it uses. The wiring behind it is −7.7% net margin on 2.42× asset turns.
FY25 ROE is −36%, recovered from a FY24 trough of −163% — the full ladder below shows the fall and the climb, undoctored.
🚨 Why the return is what it is — the wiring (FY25): −7.7% net margin × 2.42× asset turns × 1.95× balance-sheet leverage ≈ −36.3% on equity. Margin does its share; leverage is a meaningful part of the equation.
The capstone test — ROIC − WACC: −79.9% − 19.2% = a −99.1 pp spread. The 19.2% is an estimate of this company's own cost of capital — read the sign and the size of the spread, not the decimals. Negative — growth at these returns destroys value until the returns recover.
→ Returns like these — is the balance sheet borrowing to make them? Next: debt-to-equity is 0.11.
Dividend
Bed Bath & Beyond, Inc. pays no dividend. Across the last 12 reported quarters it has declared no dividend per share, so there is no payout history to chart and no yield to quote. Companies at this stage typically reinvest earnings rather than distribute them, which makes the cash-flow and reinvestment sections the place that cash shows up.
Bed Bath & Beyond, Inc. does not currently pay a dividend. Across the last 12 reported quarters the company has declared no dividend per share, so there is no payout history to chart and no yield to quote. Companies at this stage typically reinvest earnings instead of distributing them.
→ No payout to follow. The cash question becomes what the business does with what it earns instead.
Debt Debt-to-equity says how much of the business is funded by borrowings. Low is the safe corner; the trend matters as much as the level.
Bed Bath & Beyond, Inc. carries total debt of $0.0 B against shareholder equity of $0.2 B as of Mar 26, a debt-to-equity of 0.10 — effectively unlevered. On the annual view that ratio went from 0.20 in FY21 to 0.09 in FY25. The returns elsewhere on this page are therefore earned rather than borrowed.
Mar 26: total debt of $0.0 B against shareholder equity of $0.2 B — a debt-to-equity of 0.10. On the annual view, debt-to-equity went from 0.20 (FY21) to 0.09 (FY25). The returns on this page are earned, not borrowed.
→ Who owns this, and are they adding or leaving? Next: the register.
Ownership There is no quarter-by-quarter holder register to read here, so we read the crowd through short interest — the slice of tradable shares currently sold short, positioned for a fall.
No ownership or positioning reading is held for Bed Bath & Beyond, Inc., so this section names the gap rather than filling it. There is no quarter-by-quarter holder register to read for this filer, so the crowd is read through short interest instead.
We hold no ownership or positioning reading for this stock, so this section says that plainly.
→ One last check: does the safety math agree? Next: the balance-sheet safety line.
Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.
Bed Bath & Beyond, Inc.: the Z-score reads 0.43. A Z-score above roughly 3 reads as safe and below roughly 1.8 as the distress zone, so this sits inside the distress zone. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure.
🚨 Why it matters: a Z-score of 0.43 is inside the distress zone — the balance sheet is a real risk, not a detail.
The safety line in one sentence: the Z-score reads 0.43.
Frequently asked questions
What is Bed Bath & Beyond, Inc.'s stock price today?
Bed Bath & Beyond, Inc. trades at $5.3, −47.7% over the past year. The company is valued at $0.0 B. The stock sits at 12% of its 52-week range of $4–$12, −10.5% versus its 200-day average. Against the S&P 500 it has been behind on a trailing-13-week view for 3 weeks. — as of 29 July 2026.
What were Bed Bath & Beyond, Inc.'s latest quarterly results?
Bed Bath & Beyond, Inc. reported revenue of $0.3 B and a net loss of $0.0 B for the Mar 26 quarter. Earnings per share were $−0.24. The operating margin was −8.0%, 0.7 pp higher than a year earlier. — as of 29 July 2026.
What is Bed Bath & Beyond, Inc.'s revenue?
Bed Bath & Beyond, Inc. reported revenue of $0.3 B in the Mar 26 quarter, +8.7% year on year. For the full FY25 fiscal year, revenue was $1.0 B (−25.2%). Over the last 4 years revenue compounded at −21.7% a year. — as of 29 July 2026.
What is Bed Bath & Beyond, Inc.'s profit?
Bed Bath & Beyond, Inc. earned $−0.0 B of net profit in the Mar 26 quarter. Full-year FY25 profit was $−0.1 B. The operating margin ran −8.0% in the latest quarter. — as of 29 July 2026.
What is Bed Bath & Beyond, Inc.'s market cap?
Bed Bath & Beyond, Inc.'s market capitalisation is $0.0 B at a stock price of $5.3. Market cap is the share price multiplied by shares outstanding, so it is restated whenever the price moves. — as of 29 July 2026.
Does Bed Bath & Beyond, Inc. pay a dividend?
No — Bed Bath & Beyond, Inc. has declared no dividend per share in any of its last 12 reported quarters, so there is no payout history and no yield to quote. That is a reading of the filed statements, not an estimate. — as of 29 July 2026.
How is Bed Bath & Beyond, Inc. performing?
Bed Bath & Beyond, Inc.'s latest readings are below. Against the S&P 500 it has been behind on a trailing-13-week view for 3 weeks. This describes what the data did, not a rating. — as of 29 July 2026.
Is Bed Bath & Beyond, Inc. beating the market?
Not lately — on a trailing-13-week view Bed Bath & Beyond, Inc. is currently behind the S&P 500 (3 weeks and counting; last ahead the week of 2026-07-10), the same metric the week-by-week ribbon on this page draws. Separately, on the cumulative view: over the last 1.0 years the stock moved −32% against the S&P 500's +19% — behind the index over the full window. — as of 29 July 2026.
Will Bed Bath & Beyond, Inc.'s stock price go up?
This page publishes no price forecast for Bed Bath & Beyond, Inc. What it measures instead: the stock price is $5.3. Direction is not something this site claims to know. — as of 29 July 2026.
Does Bed Bath & Beyond, Inc. have too much debt?
No — Bed Bath & Beyond, Inc.'s debt-to-equity is 0.11. A year-by-year borrowings ladder is not in our numbers for this stock, so the latest reading is the cleanest hold. The returns on this page are earned, not borrowed — as of 29 July 2026.
What is Bed Bath & Beyond, Inc.'s capex?
Bed Bath & Beyond, Inc. spent $0.0 B on capital expenditure over the last 3 fiscal years, a figure derived from the change in fixed assets plus depreciation. In FY25 alone that was $0.0 B. — as of 29 July 2026.
What is Bed Bath & Beyond, Inc.'s cash flow?
Bed Bath & Beyond, Inc. generated $−0.1 B of operating cash flow in FY25 and $−0.1 B of free cash flow after $0.0 B of capital spending. Reported profit that year was $−0.1 B, so operating cash ran ahead of profit. — as of 29 July 2026.
How financially safe is Bed Bath & Beyond, Inc.?
On the balance sheet, the Z-score reads 0.43 — above roughly 3 is safe, below roughly 1.8 is the distress zone. That is inside the danger band — a real balance-sheet risk. — as of 29 July 2026.
Where is Bed Bath & Beyond, Inc. in its business cycle?
Bed Bath & Beyond, Inc.'s FY25 operating margin was −5.8%, against a 5-year band of −12.9%–4.0%: mid-band by its own history — neither the peak that precedes mean-reversion nor the trough that precedes recovery. The latest quarter ran −8.0%. Profitability versus a company's own long band is the cleanest cycle clock this page holds — as of 29 July 2026.
What could break the Bed Bath & Beyond, Inc. story?
Biggest watch item: the price is not yet in a confirmed uptrend — timing risk, not thesis risk. Mechanically, two Friday closes in a row below the 200-day average would end the price trend — that is the exit rule this page tracks — as of 29 July 2026.
Is Bed Bath & Beyond, Inc. a stock worth studying right now?
This is not investment advice. The machine read: Bed Bath & Beyond, Inc.'s three tracks disagree. Price, valuation and the earnings engine each tell a different story — the next quarter or two settles it. The sharpest open question: the next one or two quarters of delivery. Every number on this page is drawn deterministically from the raw series, with no forecasts and no price opinions — as of 29 July 2026.